Pancancer survival analysis of cancer hallmark genes
Cancer hallmark genes are responsible for the most essential phenotypic characteristics of malignant transformation and progression. In this study, our aim was to estimate the prognostic effect of the established cancer hallmark genes in multiple distinct cancer types. RNA-seq HTSeq counts and survi...
Saved in:
| Published in: | Scientific reports Vol. 11; no. 1; pp. 6047 - 10 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
Nature Publishing Group UK
15.03.2021
Nature Publishing Group Nature Portfolio |
| Subjects: | |
| ISSN: | 2045-2322, 2045-2322 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Cancer hallmark genes are responsible for the most essential phenotypic characteristics of malignant transformation and progression. In this study, our aim was to estimate the prognostic effect of the established cancer hallmark genes in multiple distinct cancer types. RNA-seq HTSeq counts and survival data from 26 different tumor types were acquired from the TCGA repository. DESeq was used for normalization. Correlations between gene expression and survival were computed using the Cox proportional hazards regression and by plotting Kaplan–Meier survival plots. The false discovery rate was calculated to correct for multiple hypothesis testing. Signatures based on genes involved in genome instability and invasion reached significance in most individual cancer types. Thyroid and glioblastoma were independent of hallmark genes (61 and 54 genes significant, respectively), while renal clear cell cancer and low grade gliomas harbored the most prognostic changes (403 and 419 genes significant, respectively). The eight genes with the highest significance included BRCA1 (genome instability, HR 4.26, p < 1E−16), RUNX1 (sustaining proliferative signaling, HR 2.96, p = 3.1E−10) and SERPINE1 (inducing angiogenesis, HR 3.36, p = 1.5E−12) in low grade glioma, CDK1 (cell death resistance, HR = 5.67, p = 2.1E−10) in kidney papillary carcinoma, E2F1 (tumor suppressor, HR 0.38, p = 2.4E−05) and EREG (enabling replicative immortality, HR 3.23, p = 2.1E−07) in cervical cancer, FBP1 (deregulation of cellular energetics, HR 0.45, p = 2.8E−07) in kidney renal clear cell carcinoma and MYC (invasion and metastasis, HR 1.81, p = 5.8E−05) in bladder cancer. We observed unexpected heterogeneity and tissue specificity when correlating cancer hallmark genes and survival. These results will help to prioritize future targeted therapy development in different types of solid tumors. |
|---|---|
| AbstractList | Cancer hallmark genes are responsible for the most essential phenotypic characteristics of malignant transformation and progression. In this study, our aim was to estimate the prognostic effect of the established cancer hallmark genes in multiple distinct cancer types. RNA-seq HTSeq counts and survival data from 26 different tumor types were acquired from the TCGA repository. DESeq was used for normalization. Correlations between gene expression and survival were computed using the Cox proportional hazards regression and by plotting Kaplan–Meier survival plots. The false discovery rate was calculated to correct for multiple hypothesis testing. Signatures based on genes involved in genome instability and invasion reached significance in most individual cancer types. Thyroid and glioblastoma were independent of hallmark genes (61 and 54 genes significant, respectively), while renal clear cell cancer and low grade gliomas harbored the most prognostic changes (403 and 419 genes significant, respectively). The eight genes with the highest significance included BRCA1 (genome instability, HR 4.26, p < 1E−16), RUNX1 (sustaining proliferative signaling, HR 2.96, p = 3.1E−10) and SERPINE1 (inducing angiogenesis, HR 3.36, p = 1.5E−12) in low grade glioma, CDK1 (cell death resistance, HR = 5.67, p = 2.1E−10) in kidney papillary carcinoma, E2F1 (tumor suppressor, HR 0.38, p = 2.4E−05) and EREG (enabling replicative immortality, HR 3.23, p = 2.1E−07) in cervical cancer, FBP1 (deregulation of cellular energetics, HR 0.45, p = 2.8E−07) in kidney renal clear cell carcinoma and MYC (invasion and metastasis, HR 1.81, p = 5.8E−05) in bladder cancer. We observed unexpected heterogeneity and tissue specificity when correlating cancer hallmark genes and survival. These results will help to prioritize future targeted therapy development in different types of solid tumors. Cancer hallmark genes are responsible for the most essential phenotypic characteristics of malignant transformation and progression. In this study, our aim was to estimate the prognostic effect of the established cancer hallmark genes in multiple distinct cancer types. RNA-seq HTSeq counts and survival data from 26 different tumor types were acquired from the TCGA repository. DESeq was used for normalization. Correlations between gene expression and survival were computed using the Cox proportional hazards regression and by plotting Kaplan-Meier survival plots. The false discovery rate was calculated to correct for multiple hypothesis testing. Signatures based on genes involved in genome instability and invasion reached significance in most individual cancer types. Thyroid and glioblastoma were independent of hallmark genes (61 and 54 genes significant, respectively), while renal clear cell cancer and low grade gliomas harbored the most prognostic changes (403 and 419 genes significant, respectively). The eight genes with the highest significance included BRCA1 (genome instability, HR 4.26, p < 1E-16), RUNX1 (sustaining proliferative signaling, HR 2.96, p = 3.1E-10) and SERPINE1 (inducing angiogenesis, HR 3.36, p = 1.5E-12) in low grade glioma, CDK1 (cell death resistance, HR = 5.67, p = 2.1E-10) in kidney papillary carcinoma, E2F1 (tumor suppressor, HR 0.38, p = 2.4E-05) and EREG (enabling replicative immortality, HR 3.23, p = 2.1E-07) in cervical cancer, FBP1 (deregulation of cellular energetics, HR 0.45, p = 2.8E-07) in kidney renal clear cell carcinoma and MYC (invasion and metastasis, HR 1.81, p = 5.8E-05) in bladder cancer. We observed unexpected heterogeneity and tissue specificity when correlating cancer hallmark genes and survival. These results will help to prioritize future targeted therapy development in different types of solid tumors.Cancer hallmark genes are responsible for the most essential phenotypic characteristics of malignant transformation and progression. In this study, our aim was to estimate the prognostic effect of the established cancer hallmark genes in multiple distinct cancer types. RNA-seq HTSeq counts and survival data from 26 different tumor types were acquired from the TCGA repository. DESeq was used for normalization. Correlations between gene expression and survival were computed using the Cox proportional hazards regression and by plotting Kaplan-Meier survival plots. The false discovery rate was calculated to correct for multiple hypothesis testing. Signatures based on genes involved in genome instability and invasion reached significance in most individual cancer types. Thyroid and glioblastoma were independent of hallmark genes (61 and 54 genes significant, respectively), while renal clear cell cancer and low grade gliomas harbored the most prognostic changes (403 and 419 genes significant, respectively). The eight genes with the highest significance included BRCA1 (genome instability, HR 4.26, p < 1E-16), RUNX1 (sustaining proliferative signaling, HR 2.96, p = 3.1E-10) and SERPINE1 (inducing angiogenesis, HR 3.36, p = 1.5E-12) in low grade glioma, CDK1 (cell death resistance, HR = 5.67, p = 2.1E-10) in kidney papillary carcinoma, E2F1 (tumor suppressor, HR 0.38, p = 2.4E-05) and EREG (enabling replicative immortality, HR 3.23, p = 2.1E-07) in cervical cancer, FBP1 (deregulation of cellular energetics, HR 0.45, p = 2.8E-07) in kidney renal clear cell carcinoma and MYC (invasion and metastasis, HR 1.81, p = 5.8E-05) in bladder cancer. We observed unexpected heterogeneity and tissue specificity when correlating cancer hallmark genes and survival. These results will help to prioritize future targeted therapy development in different types of solid tumors. Abstract Cancer hallmark genes are responsible for the most essential phenotypic characteristics of malignant transformation and progression. In this study, our aim was to estimate the prognostic effect of the established cancer hallmark genes in multiple distinct cancer types. RNA-seq HTSeq counts and survival data from 26 different tumor types were acquired from the TCGA repository. DESeq was used for normalization. Correlations between gene expression and survival were computed using the Cox proportional hazards regression and by plotting Kaplan–Meier survival plots. The false discovery rate was calculated to correct for multiple hypothesis testing. Signatures based on genes involved in genome instability and invasion reached significance in most individual cancer types. Thyroid and glioblastoma were independent of hallmark genes (61 and 54 genes significant, respectively), while renal clear cell cancer and low grade gliomas harbored the most prognostic changes (403 and 419 genes significant, respectively). The eight genes with the highest significance included BRCA1 (genome instability, HR 4.26, p < 1E−16), RUNX1 (sustaining proliferative signaling, HR 2.96, p = 3.1E−10) and SERPINE1 (inducing angiogenesis, HR 3.36, p = 1.5E−12) in low grade glioma, CDK1 (cell death resistance, HR = 5.67, p = 2.1E−10) in kidney papillary carcinoma, E2F1 (tumor suppressor, HR 0.38, p = 2.4E−05) and EREG (enabling replicative immortality, HR 3.23, p = 2.1E−07) in cervical cancer, FBP1 (deregulation of cellular energetics, HR 0.45, p = 2.8E−07) in kidney renal clear cell carcinoma and MYC (invasion and metastasis, HR 1.81, p = 5.8E−05) in bladder cancer. We observed unexpected heterogeneity and tissue specificity when correlating cancer hallmark genes and survival. These results will help to prioritize future targeted therapy development in different types of solid tumors. Cancer hallmark genes are responsible for the most essential phenotypic characteristics of malignant transformation and progression. In this study, our aim was to estimate the prognostic effect of the established cancer hallmark genes in multiple distinct cancer types. RNA-seq HTSeq counts and survival data from 26 different tumor types were acquired from the TCGA repository. DESeq was used for normalization. Correlations between gene expression and survival were computed using the Cox proportional hazards regression and by plotting Kaplan-Meier survival plots. The false discovery rate was calculated to correct for multiple hypothesis testing. Signatures based on genes involved in genome instability and invasion reached significance in most individual cancer types. Thyroid and glioblastoma were independent of hallmark genes (61 and 54 genes significant, respectively), while renal clear cell cancer and low grade gliomas harbored the most prognostic changes (403 and 419 genes significant, respectively). The eight genes with the highest significance included BRCA1 (genome instability, HR 4.26, p < 1E-16), RUNX1 (sustaining proliferative signaling, HR 2.96, p = 3.1E-10) and SERPINE1 (inducing angiogenesis, HR 3.36, p = 1.5E-12) in low grade glioma, CDK1 (cell death resistance, HR = 5.67, p = 2.1E-10) in kidney papillary carcinoma, E2F1 (tumor suppressor, HR 0.38, p = 2.4E-05) and EREG (enabling replicative immortality, HR 3.23, p = 2.1E-07) in cervical cancer, FBP1 (deregulation of cellular energetics, HR 0.45, p = 2.8E-07) in kidney renal clear cell carcinoma and MYC (invasion and metastasis, HR 1.81, p = 5.8E-05) in bladder cancer. We observed unexpected heterogeneity and tissue specificity when correlating cancer hallmark genes and survival. These results will help to prioritize future targeted therapy development in different types of solid tumors. |
| ArticleNumber | 6047 |
| Author | Győrffy, Balázs Nagy, Ádám Munkácsy, Gyöngyi |
| Author_xml | – sequence: 1 givenname: Ádám surname: Nagy fullname: Nagy, Ádám organization: Department of Bioinformatics, Semmelweis University, TTK Momentum Cancer Biomarker Research Group – sequence: 2 givenname: Gyöngyi surname: Munkácsy fullname: Munkácsy, Gyöngyi organization: Department of Bioinformatics, Semmelweis University – sequence: 3 givenname: Balázs surname: Győrffy fullname: Győrffy, Balázs email: gyorffy.balazs@med.semmelweis-univ.hu organization: Department of Bioinformatics, Semmelweis University, TTK Momentum Cancer Biomarker Research Group |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33723286$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UktLHTEYDWKpj_oHXJSBbtxMm8fktSkUqVYQ2kW7Dpnkm2tucyc2mbngv290rq26MAQSch6cJOcI7Y9pBIROCf5IMFOfSke4Vi2mpFWdVLLle-iQ4o63lFG6_2R_gE5KWeM6ONUd0W_RAWOyIkocou6HHV2dkJsy523Y2tjY0ca7EkqThmaH3dgYNzb_blYwQnmH3gw2FjjZrcfo18XXn-ff2uvvl1fnX65bJ7CYWs05lg4L7zUokEAcHgS4XnPqmdIeE0V1P1DfcQe4twM44aDCjmthPWPH6Grx9cmuzW0ONcKdSTaYh4OUV8bmKbgIpnPAeyEZYR466wbtuCeKy54ojCnV1evz4nU79xvwDsYp2_jM9DkyhhuzSlsjtSAYk2pwtjPI6c8MZTKbUBzEaEdIczGU1_tw2ilZqR9eUNdpzvVVFxbjklNVWe-fJvoX5fFzKkEtBJdTKRkG48Jkp5DuA4ZoCDb3VTBLFUytgnmoguFVSl9IH91fFbFFVCp5XEH-H_sV1V_bd8VV |
| CitedBy_id | crossref_primary_10_1158_1541_7786_MCR_24_0120 crossref_primary_10_3390_cancers15164167 crossref_primary_10_1016_j_tranon_2024_102146 crossref_primary_10_1210_endocr_bqae110 crossref_primary_10_1038_s41598_024_51720_5 crossref_primary_10_2174_1381612829666230816100623 crossref_primary_10_1038_s41598_025_97629_5 crossref_primary_10_3390_biom11081193 crossref_primary_10_1080_21655979_2021_1960464 crossref_primary_10_1016_j_molcel_2021_10_013 crossref_primary_10_1002_cam4_4163 crossref_primary_10_1016_j_jbc_2022_101644 crossref_primary_10_3390_v15040853 crossref_primary_10_1016_j_jbc_2022_102734 crossref_primary_10_1186_s13578_022_00778_7 crossref_primary_10_4103_jcrt_jcrt_1120_21 crossref_primary_10_1096_fba_2024_00190 crossref_primary_10_3389_fonc_2021_752604 crossref_primary_10_1016_j_ygeno_2021_11_037 crossref_primary_10_3390_ph15070824 crossref_primary_10_3389_fonc_2022_829705 crossref_primary_10_1016_j_chembiol_2022_07_002 crossref_primary_10_3390_biomedicines9091144 crossref_primary_10_3892_ol_2023_14119 crossref_primary_10_3390_cancers13164098 crossref_primary_10_1371_journal_pbio_3002739 crossref_primary_10_3390_cancers14215180 crossref_primary_10_1038_s41419_023_05566_w crossref_primary_10_1371_journal_pone_0280364 crossref_primary_10_3390_biomedicines11020270 crossref_primary_10_1016_j_gene_2021_145994 crossref_primary_10_1186_s12864_021_08137_5 crossref_primary_10_3389_fgene_2021_749435 crossref_primary_10_1038_s41418_024_01430_2 crossref_primary_10_1155_2024_9436238 crossref_primary_10_3389_fendo_2021_743155 crossref_primary_10_1016_j_jid_2024_07_022 crossref_primary_10_1016_j_archoralbio_2022_105519 crossref_primary_10_3389_fmed_2022_968081 crossref_primary_10_3389_fonc_2023_1112859 crossref_primary_10_1038_s41598_022_15866_4 crossref_primary_10_1155_2022_9443407 crossref_primary_10_3389_fgene_2021_737656 crossref_primary_10_1016_j_compbiomed_2021_104793 crossref_primary_10_1002_cam4_5397 crossref_primary_10_1186_s12935_021_02266_3 crossref_primary_10_3390_cimb47090757 crossref_primary_10_1177_17588359241247019 crossref_primary_10_1016_j_yexcr_2021_112763 crossref_primary_10_3389_fendo_2021_826667 crossref_primary_10_3389_fimmu_2021_723293 crossref_primary_10_1016_j_isci_2024_110318 crossref_primary_10_1155_2021_2805576 crossref_primary_10_3390_app13158935 crossref_primary_10_1186_s12876_023_02672_z crossref_primary_10_1038_s41598_021_90126_5 crossref_primary_10_1016_j_tranon_2024_102056 crossref_primary_10_3390_cancers15194723 crossref_primary_10_3390_healthcare12090939 crossref_primary_10_3390_ijms23010215 crossref_primary_10_3389_fcell_2021_730538 crossref_primary_10_1155_2022_4948943 crossref_primary_10_1002_mco2_70000 crossref_primary_10_1177_02611929221107546 crossref_primary_10_3389_fcell_2021_695544 crossref_primary_10_7717_peerj_12171 crossref_primary_10_3389_fonc_2022_781686 crossref_primary_10_1186_s12865_022_00485_5 crossref_primary_10_3390_diagnostics12123190 crossref_primary_10_1016_j_cmpb_2023_107373 crossref_primary_10_1016_j_mcp_2021_101759 crossref_primary_10_1093_nar_gkae1126 crossref_primary_10_3390_cells10082091 crossref_primary_10_3389_fmolb_2022_818470 crossref_primary_10_1186_s12935_021_02278_z crossref_primary_10_3389_fmolb_2021_799497 crossref_primary_10_7717_peerj_18428 crossref_primary_10_1186_s13040_022_00312_y crossref_primary_10_3390_biomedicines11102655 crossref_primary_10_3390_ijms22116001 crossref_primary_10_1016_j_neo_2025_101220 crossref_primary_10_3390_genes14061250 crossref_primary_10_1016_j_jpha_2024_101065 crossref_primary_10_1016_j_prp_2022_153809 crossref_primary_10_1093_bjc_azae023 crossref_primary_10_1080_21655979_2021_1973220 crossref_primary_10_1186_s12885_025_14304_8 crossref_primary_10_3389_fimmu_2021_774435 crossref_primary_10_3389_fonc_2021_737127 crossref_primary_10_1016_j_celrep_2024_114088 crossref_primary_10_7759_cureus_64640 crossref_primary_10_1186_s12885_024_13257_8 crossref_primary_10_1002_advs_202304203 crossref_primary_10_1002_1878_0261_12999 crossref_primary_10_3390_cells10092179 crossref_primary_10_3389_fimmu_2021_781087 crossref_primary_10_3390_ijms23136993 crossref_primary_10_1007_s12672_025_01880_1 crossref_primary_10_3389_fmolb_2022_887059 crossref_primary_10_3892_etm_2022_11509 crossref_primary_10_1111_cas_15359 crossref_primary_10_3390_ijms241914758 crossref_primary_10_1186_s13046_024_03232_3 crossref_primary_10_1038_s41598_024_57771_y crossref_primary_10_1002_2211_5463_13654 crossref_primary_10_1016_j_cell_2022_07_025 crossref_primary_10_3389_fonc_2021_727583 crossref_primary_10_3390_cancers14174120 crossref_primary_10_1007_s12672_025_02259_y crossref_primary_10_3389_fonc_2021_714756 crossref_primary_10_3389_fonc_2021_790912 crossref_primary_10_3390_ijms22157882 crossref_primary_10_3389_fgene_2022_952528 crossref_primary_10_3389_fonc_2021_777834 crossref_primary_10_1016_j_gene_2023_147692 crossref_primary_10_3389_fgene_2021_745277 crossref_primary_10_3389_fgene_2023_1162787 crossref_primary_10_3390_cancers14205060 crossref_primary_10_3390_ijms231810316 crossref_primary_10_1038_s41598_024_53489_z crossref_primary_10_1515_jcim_2023_0262 crossref_primary_10_3389_fmolb_2022_790706 crossref_primary_10_3390_healthcare12191982 crossref_primary_10_1002_cbic_202500551 crossref_primary_10_1186_s12859_024_05932_1 crossref_primary_10_3389_fonc_2022_828849 crossref_primary_10_1080_21655979_2021_1951928 crossref_primary_10_1245_s10434_021_11132_5 crossref_primary_10_1002_cam4_5238 crossref_primary_10_3390_ijerph19010416 crossref_primary_10_1007_s10565_021_09651_8 crossref_primary_10_1016_j_biopha_2022_113675 crossref_primary_10_3390_ijms222413297 crossref_primary_10_1186_s12894_021_00938_w crossref_primary_10_1038_s41598_022_19299_x crossref_primary_10_3390_pharmaceutics15020427 crossref_primary_10_1038_s41467_022_30323_6 crossref_primary_10_1186_s12876_022_02423_6 crossref_primary_10_3389_fonc_2022_882328 crossref_primary_10_1007_s00497_025_00526_0 crossref_primary_10_52547_ibj_3671 crossref_primary_10_1016_j_clinre_2022_101891 crossref_primary_10_1038_s41598_024_64687_0 crossref_primary_10_1159_000535542 crossref_primary_10_1007_s12070_025_05751_7 crossref_primary_10_3390_ijms241210190 crossref_primary_10_3390_ijms221910817 crossref_primary_10_1016_j_bbrc_2025_152342 crossref_primary_10_3389_fmolb_2021_788690 crossref_primary_10_1016_j_urolonc_2024_05_015 crossref_primary_10_1155_2022_9110704 crossref_primary_10_1016_j_jormas_2024_102041 crossref_primary_10_3389_fgene_2022_874667 crossref_primary_10_3389_fmed_2023_1107128 crossref_primary_10_1111_cas_16236 crossref_primary_10_3390_cells11091421 crossref_primary_10_1007_s00018_021_04120_1 crossref_primary_10_1016_j_drup_2024_101154 crossref_primary_10_1016_j_ejmech_2024_116841 crossref_primary_10_3390_jpm12091436 crossref_primary_10_1016_j_heliyon_2024_e35202 crossref_primary_10_2147_IJGM_S350971 crossref_primary_10_1097_MD_0000000000030270 crossref_primary_10_3389_fonc_2022_877878 crossref_primary_10_1109_JBHI_2024_3362850 crossref_primary_10_1155_2022_3379027 crossref_primary_10_3389_fcell_2021_705828 crossref_primary_10_1186_s12885_021_08674_y crossref_primary_10_3390_ncrna8060072 crossref_primary_10_3390_ijms24044015 crossref_primary_10_2147_IJGM_S328225 crossref_primary_10_3389_fonc_2022_821958 crossref_primary_10_1007_s10142_023_01191_0 crossref_primary_10_1016_j_canlet_2021_12_033 crossref_primary_10_1016_j_omtn_2021_06_024 crossref_primary_10_1186_s12935_025_03880_1 crossref_primary_10_3390_genes16060674 crossref_primary_10_1177_15353702211035693 crossref_primary_10_3389_fphar_2022_851089 crossref_primary_10_3892_ol_2023_13663 crossref_primary_10_1128_msphere_00317_22 crossref_primary_10_1080_07391102_2023_2167122 crossref_primary_10_3390_life12081269 crossref_primary_10_1080_07391102_2024_2316771 crossref_primary_10_3389_fgene_2022_895281 crossref_primary_10_1038_s42003_023_04437_6 crossref_primary_10_3389_fonc_2021_612952 crossref_primary_10_1002_mco2_85 crossref_primary_10_3389_fonc_2021_762946 crossref_primary_10_3390_jpm11080782 crossref_primary_10_3389_fgene_2021_763561 crossref_primary_10_1007_s00262_024_03656_y crossref_primary_10_3389_fonc_2021_743050 crossref_primary_10_3389_fonc_2021_681717 crossref_primary_10_3390_diagnostics13091613 crossref_primary_10_1002_adbi_202200020 crossref_primary_10_1016_j_archoralbio_2024_106090 crossref_primary_10_1016_j_bspc_2024_107240 crossref_primary_10_1016_j_compbiomed_2025_110044 crossref_primary_10_3390_ijms24032049 crossref_primary_10_7717_peerj_16263 crossref_primary_10_1002_ctm2_1432 crossref_primary_10_1186_s12929_022_00826_x crossref_primary_10_1038_s41598_024_60975_x crossref_primary_10_2147_IJGM_S342741 crossref_primary_10_1016_j_omtn_2021_06_005 crossref_primary_10_1158_2326_6066_CIR_20_0327 crossref_primary_10_1038_s41419_022_04940_4 crossref_primary_10_1016_j_jbc_2023_104814 crossref_primary_10_1016_j_bbrc_2025_152313 crossref_primary_10_1155_2021_6485871 crossref_primary_10_1007_s13205_022_03140_3 crossref_primary_10_1038_s41388_022_02224_x crossref_primary_10_1007_s00432_021_03819_9 crossref_primary_10_3390_biology11040590 crossref_primary_10_3390_cancers13153823 crossref_primary_10_1016_j_jnutbio_2023_109438 crossref_primary_10_1016_j_omtn_2022_01_011 crossref_primary_10_1038_s41698_024_00555_4 crossref_primary_10_3390_cancers13153822 crossref_primary_10_1155_2022_4651432 crossref_primary_10_1038_s41598_024_69638_3 crossref_primary_10_1016_j_cancergen_2022_09_003 crossref_primary_10_1155_2022_5939021 crossref_primary_10_1016_j_gande_2022_11_006 crossref_primary_10_1038_s41598_022_05922_4 crossref_primary_10_1155_2024_9279653 crossref_primary_10_2147_JIR_S341001 crossref_primary_10_1007_s10528_021_10178_0 crossref_primary_10_3389_fonc_2021_738607 crossref_primary_10_3233_CBM_210559 crossref_primary_10_3389_pore_2021_1609821 crossref_primary_10_1016_j_csbj_2021_08_047 crossref_primary_10_1007_s12020_024_03836_x crossref_primary_10_1097_MD_0000000000029802 crossref_primary_10_3390_biomedicines10071727 crossref_primary_10_1021_acsami_5c02782 crossref_primary_10_3390_cancers13195004 crossref_primary_10_1038_s43018_024_00771_8 crossref_primary_10_1080_09553002_2023_2194390 crossref_primary_10_3390_cells12030437 crossref_primary_10_1186_s12885_022_09180_5 crossref_primary_10_3389_pore_2022_1610554 crossref_primary_10_3390_genes15091167 crossref_primary_10_1155_2022_5943529 crossref_primary_10_3892_ijmm_2025_5509 crossref_primary_10_1093_nar_gkac114 crossref_primary_10_1007_s11010_022_04607_w crossref_primary_10_1038_s41598_021_04007_y crossref_primary_10_1038_s41598_024_65425_2 crossref_primary_10_3892_ol_2025_15099 crossref_primary_10_1016_j_knosys_2025_113295 crossref_primary_10_1158_0008_5472_CAN_23_0379 crossref_primary_10_3390_toxics11100856 crossref_primary_10_1016_j_heliyon_2023_e13543 crossref_primary_10_1186_s12885_023_10616_9 crossref_primary_10_3390_cancers15204915 crossref_primary_10_1002_tox_23370 crossref_primary_10_3389_fcell_2021_719187 crossref_primary_10_1016_j_celrep_2023_113426 crossref_primary_10_1021_acs_jproteome_5c00273 crossref_primary_10_1158_2159_8290_CD_21_0683 crossref_primary_10_3389_fcell_2022_918544 crossref_primary_10_1051_bioconf_202411101014 crossref_primary_10_3389_pore_2022_1610687 crossref_primary_10_1016_j_biopha_2021_112431 crossref_primary_10_1016_j_cellsig_2024_111110 crossref_primary_10_1186_s12894_023_01258_x crossref_primary_10_7759_cureus_50995 crossref_primary_10_3892_or_2022_8399 crossref_primary_10_1016_j_tice_2022_101845 crossref_primary_10_1038_s41598_023_39827_7 crossref_primary_10_1080_19336950_2021_2004758 crossref_primary_10_1186_s12864_023_09893_2 crossref_primary_10_1038_s43018_023_00697_7 crossref_primary_10_1038_s41586_021_03422_5 crossref_primary_10_1002_cti2_1305 crossref_primary_10_1016_j_ygeno_2021_12_011 crossref_primary_10_1002_tox_23347 crossref_primary_10_1155_2022_4338793 crossref_primary_10_3389_fonc_2023_1175958 crossref_primary_10_1016_j_canlet_2021_04_007 crossref_primary_10_1158_0008_5472_CAN_23_3628 crossref_primary_10_3389_fonc_2021_713017 crossref_primary_10_3390_cancers16010128 crossref_primary_10_1016_j_jep_2022_115647 crossref_primary_10_3389_fcell_2021_748925 crossref_primary_10_1002_mc_23831 crossref_primary_10_1186_s12920_023_01463_5 crossref_primary_10_3390_cancers16162893 crossref_primary_10_1016_j_heliyon_2024_e28090 crossref_primary_10_1186_s12879_023_08942_1 crossref_primary_10_1007_s10238_022_00952_8 crossref_primary_10_1016_j_ajoms_2025_04_014 crossref_primary_10_1186_s12967_023_04001_0 crossref_primary_10_1007_s13369_022_07540_8 crossref_primary_10_1261_rna_078886_121 crossref_primary_10_5688_ajpe8683 crossref_primary_10_1016_j_gastha_2024_09_007 crossref_primary_10_3390_cancers14235980 crossref_primary_10_1016_j_molstruc_2024_139675 crossref_primary_10_3350_cmh_2021_0394 crossref_primary_10_1007_s00595_023_02655_3 crossref_primary_10_1016_j_trsl_2022_09_004 crossref_primary_10_3390_cancers13153752 crossref_primary_10_1371_journal_pone_0299353 crossref_primary_10_2147_IJGM_S330500 crossref_primary_10_1016_j_intimp_2021_108454 crossref_primary_10_3390_genes12081254 crossref_primary_10_1038_s41392_022_00944_w crossref_primary_10_1080_14622416_2024_2355864 crossref_primary_10_3390_cancers13174348 crossref_primary_10_1016_j_prp_2022_154027 crossref_primary_10_2147_IJGM_S329031 crossref_primary_10_3390_ijms222413636 crossref_primary_10_3389_fphar_2022_1080055 crossref_primary_10_1016_j_heliyon_2024_e40329 crossref_primary_10_1002_jcb_30417 crossref_primary_10_1073_pnas_2409447121 crossref_primary_10_1097_MD_0000000000041761 crossref_primary_10_1016_j_heliyon_2024_e28794 crossref_primary_10_1038_s41419_021_04252_z crossref_primary_10_1002_1873_3468_14296 crossref_primary_10_3389_fimmu_2022_756928 crossref_primary_10_1186_s12967_022_03503_7 crossref_primary_10_3390_ijms242316740 crossref_primary_10_3389_fbioe_2021_744659 crossref_primary_10_1038_s41416_022_01794_7 crossref_primary_10_1158_1078_0432_CCR_21_4272 crossref_primary_10_3390_ijms222312828 crossref_primary_10_1016_j_celrep_2024_114616 crossref_primary_10_3389_fimmu_2023_1209249 crossref_primary_10_1016_j_ijbiomac_2022_09_203 crossref_primary_10_3389_fgene_2022_967378 crossref_primary_10_1007_s00018_025_05693_x crossref_primary_10_1016_j_jormas_2024_101811 crossref_primary_10_3390_jpm11111089 crossref_primary_10_1016_j_eti_2022_102893 crossref_primary_10_1016_j_biopha_2023_115349 crossref_primary_10_1007_s12026_022_09323_7 crossref_primary_10_1007_s12672_021_00434_5 crossref_primary_10_3390_biom11070969 crossref_primary_10_1371_journal_pone_0308585 crossref_primary_10_1080_19768354_2022_2107070 crossref_primary_10_47495_okufbed_1555255 crossref_primary_10_1155_2022_2676114 crossref_primary_10_1038_s41598_022_05549_5 crossref_primary_10_1016_j_humgen_2022_201067 crossref_primary_10_1016_j_heliyon_2023_e16152 crossref_primary_10_1186_s13046_021_01999_3 crossref_primary_10_1038_s12276_025_01407_2 crossref_primary_10_31083_j_fbl2705167 crossref_primary_10_1186_s13073_024_01287_7 crossref_primary_10_3390_cells12020336 crossref_primary_10_1038_s41598_022_19247_9 crossref_primary_10_1002_ijc_35405 crossref_primary_10_1186_s12885_021_08785_6 crossref_primary_10_3390_jof8070733 crossref_primary_10_1016_j_talanta_2024_127024 crossref_primary_10_1002_cac2_12408 crossref_primary_10_1186_s12885_021_08992_1 crossref_primary_10_3389_fonc_2022_1039145 crossref_primary_10_3389_fphar_2022_996686 crossref_primary_10_3390_biomedicines10123037 crossref_primary_10_3390_biomedicines11030896 crossref_primary_10_1038_s41598_024_76210_6 crossref_primary_10_1080_15257770_2025_2535749 crossref_primary_10_3390_cells11152311 crossref_primary_10_3389_fcell_2023_1168462 crossref_primary_10_1021_acs_jcim_5c00689 crossref_primary_10_3892_ol_2022_13494 crossref_primary_10_1177_03946320231184997 crossref_primary_10_1158_1541_7786_MCR_23_1075 crossref_primary_10_3389_fonc_2021_742017 crossref_primary_10_7717_peerj_19489 crossref_primary_10_1002_anie_202217408 crossref_primary_10_1155_2022_5357114 crossref_primary_10_1186_s12859_023_05165_8 crossref_primary_10_1016_j_intimp_2022_109008 crossref_primary_10_3892_etm_2021_10976 crossref_primary_10_1073_pnas_2103592118 crossref_primary_10_1016_j_molcel_2023_11_023 crossref_primary_10_1038_s41467_023_35784_x crossref_primary_10_3390_ijms23137158 crossref_primary_10_3390_biology10050407 crossref_primary_10_1016_j_jep_2022_116125 crossref_primary_10_1038_s41598_024_61426_3 crossref_primary_10_1155_2022_5288075 crossref_primary_10_3389_fcell_2021_738709 crossref_primary_10_1111_jop_13470 crossref_primary_10_3389_fmolb_2024_1387919 crossref_primary_10_1038_s41586_024_07328_w crossref_primary_10_3390_cancers16244178 crossref_primary_10_1016_j_jsbmb_2024_106623 crossref_primary_10_1038_s41467_022_31919_8 crossref_primary_10_3390_biology13100793 crossref_primary_10_1016_j_bbadis_2024_167533 crossref_primary_10_1016_j_compbiomed_2022_106036 crossref_primary_10_1158_0008_5472_CAN_21_3910 crossref_primary_10_1186_s12935_021_02193_3 crossref_primary_10_1097_MD_0000000000028869 crossref_primary_10_3389_fonc_2021_759952 crossref_primary_10_1097_MD_0000000000042933 crossref_primary_10_1016_j_prp_2022_154111 crossref_primary_10_1089_omi_2023_0053 crossref_primary_10_1093_bib_bbad062 crossref_primary_10_1158_1541_7786_MCR_21_0772 crossref_primary_10_3389_fimmu_2022_864244 crossref_primary_10_1093_bib_bbac090 crossref_primary_10_1016_j_bbrc_2023_08_039 crossref_primary_10_3390_ijms232214102 crossref_primary_10_3390_ph17020152 crossref_primary_10_3389_fmolb_2022_862932 crossref_primary_10_1093_nargab_lqae133 crossref_primary_10_2217_fon_2021_0275 crossref_primary_10_3390_ijms26135937 crossref_primary_10_3390_ijms24119258 crossref_primary_10_1002_cbin_12087 crossref_primary_10_3389_fgene_2022_866473 crossref_primary_10_3389_fonc_2021_736725 crossref_primary_10_1186_s12964_023_01148_7 crossref_primary_10_1155_2022_9983351 crossref_primary_10_1073_pnas_2205247120 crossref_primary_10_1186_s12920_022_01380_z crossref_primary_10_3389_fonc_2022_1071722 crossref_primary_10_1186_s12885_023_10866_7 crossref_primary_10_3389_fonc_2022_890154 crossref_primary_10_31083_j_fbl2810243 crossref_primary_10_3389_pore_2021_1609914 crossref_primary_10_1002_advs_202401230 crossref_primary_10_1186_s40246_025_00744_7 crossref_primary_10_1007_s10266_023_00883_0 crossref_primary_10_1158_1078_0432_CCR_21_0987 crossref_primary_10_3389_fgene_2021_764245 crossref_primary_10_3389_fonc_2023_1082441 crossref_primary_10_2174_1574893617666220802154148 crossref_primary_10_1016_j_jth_2024_101777 crossref_primary_10_1016_j_cbi_2023_110443 crossref_primary_10_1016_j_bbrc_2024_149575 crossref_primary_10_3390_ijms24020978 crossref_primary_10_1007_s12094_022_02835_6 crossref_primary_10_3389_fgene_2022_856692 crossref_primary_10_3892_ol_2021_13101 crossref_primary_10_1016_j_isci_2023_106103 crossref_primary_10_3390_cancers13061433 crossref_primary_10_1080_21655979_2021_1979353 crossref_primary_10_1186_s12967_021_02825_2 crossref_primary_10_3390_ijms24065168 crossref_primary_10_1016_j_archoralbio_2024_105926 crossref_primary_10_1038_s41598_025_88339_z crossref_primary_10_1089_ars_2021_0251 crossref_primary_10_1038_s41467_022_31764_9 crossref_primary_10_1038_s41598_024_60342_w crossref_primary_10_1111_liv_14972 crossref_primary_10_3390_bioengineering9080406 crossref_primary_10_3390_cancers13164118 crossref_primary_10_1186_s41065_022_00229_w crossref_primary_10_1186_s11658_022_00342_8 crossref_primary_10_1007_s12672_022_00587_x crossref_primary_10_3390_diagnostics14050468 crossref_primary_10_3389_fonc_2023_1047588 crossref_primary_10_1016_j_ygeno_2022_110425 crossref_primary_10_31083_j_fbl2706196 crossref_primary_10_2147_IJGM_S354195 crossref_primary_10_1155_2022_1494520 crossref_primary_10_1007_s43450_025_00690_4 crossref_primary_10_1155_2022_7117014 crossref_primary_10_1109_JBHI_2024_3397955 crossref_primary_10_3389_fchem_2022_1024670 crossref_primary_10_3389_fimmu_2022_1001173 crossref_primary_10_3390_ijms241914786 crossref_primary_10_3389_fphar_2024_1486265 crossref_primary_10_1002_hed_26944 crossref_primary_10_3389_fmolb_2021_810864 crossref_primary_10_1007_s40944_024_00922_w crossref_primary_10_1186_s13008_024_00130_0 crossref_primary_10_3390_cancers14102544 crossref_primary_10_1016_j_jri_2022_103658 crossref_primary_10_1016_j_mtcomm_2023_105461 crossref_primary_10_1093_bib_bbaf209 crossref_primary_10_1016_j_ebiom_2023_104452 crossref_primary_10_1016_j_yexcr_2022_113078 crossref_primary_10_1002_1878_0261_13140 crossref_primary_10_2478_raon_2024_0020 crossref_primary_10_1136_jitc_2022_006457 crossref_primary_10_3390_ijms25042398 crossref_primary_10_1038_s41391_024_00918_9 crossref_primary_10_1016_j_cellsig_2023_110914 crossref_primary_10_7717_peerj_15749 crossref_primary_10_1007_s00432_022_04106_x crossref_primary_10_1002_cbin_11741 crossref_primary_10_3390_cancers13133192 crossref_primary_10_1016_j_ijbiomac_2024_139273 crossref_primary_10_23736_S1825_859X_22_00142_6 crossref_primary_10_1016_j_compbiomed_2021_104986 crossref_primary_10_1016_j_jobcr_2025_08_024 crossref_primary_10_1042_BCJ20220101 crossref_primary_10_1186_s12967_022_03802_z crossref_primary_10_1371_journal_pone_0281182 crossref_primary_10_1111_cas_16133 crossref_primary_10_3389_fmolb_2021_744363 crossref_primary_10_2174_0115701808255183230922110002 crossref_primary_10_3389_fonc_2021_691199 crossref_primary_10_3390_cancers14092084 crossref_primary_10_1038_s41467_025_59886_w crossref_primary_10_1007_s11010_023_04776_2 crossref_primary_10_1158_0008_5472_CAN_23_0966 crossref_primary_10_3389_fimmu_2021_709493 crossref_primary_10_1007_s12672_022_00503_3 crossref_primary_10_1038_s41419_024_06749_9 crossref_primary_10_3390_genes13050902 crossref_primary_10_1038_s41467_024_45698_x crossref_primary_10_3389_fcell_2022_891731 crossref_primary_10_1172_JCI165863 crossref_primary_10_1016_j_cellsig_2022_110405 crossref_primary_10_1093_bib_bbad292 crossref_primary_10_3389_fmolb_2022_1036287 crossref_primary_10_1186_s13000_024_01474_5 crossref_primary_10_3389_fmolb_2023_1017148 crossref_primary_10_3892_ol_2021_13133 crossref_primary_10_1038_s41698_025_01029_x crossref_primary_10_1371_journal_pone_0255915 crossref_primary_10_1186_s10020_025_01213_6 crossref_primary_10_3390_genes16030310 crossref_primary_10_1007_s00795_023_00353_0 crossref_primary_10_1016_j_csbj_2022_07_021 crossref_primary_10_3389_fgene_2021_757582 crossref_primary_10_1186_s12920_023_01676_8 crossref_primary_10_1007_s00432_023_04797_w crossref_primary_10_1007_s10495_022_01763_8 crossref_primary_10_3389_fphar_2021_701454 crossref_primary_10_3389_fimmu_2023_1102824 crossref_primary_10_3390_jpm12111919 crossref_primary_10_1016_j_tranon_2022_101442 crossref_primary_10_1016_j_ccell_2024_09_007 crossref_primary_10_1016_j_labinv_2024_102131 crossref_primary_10_1155_2023_4926474 crossref_primary_10_3389_fmolb_2022_1017036 crossref_primary_10_1038_s41419_022_05071_6 crossref_primary_10_1155_2022_7073472 crossref_primary_10_3389_fimmu_2024_1374068 crossref_primary_10_3892_or_2021_8127 crossref_primary_10_1155_2021_1901191 crossref_primary_10_1016_j_humgen_2022_201119 crossref_primary_10_3390_ph16030389 crossref_primary_10_1007_s00018_022_04487_9 crossref_primary_10_3389_fgene_2022_813285 crossref_primary_10_1038_s41523_022_00485_z crossref_primary_10_3389_fgene_2023_1087432 crossref_primary_10_1007_s10528_025_11118_y crossref_primary_10_1038_s41594_024_01329_z crossref_primary_10_1186_s12929_021_00757_z crossref_primary_10_1038_s41598_022_09889_0 crossref_primary_10_1093_bib_bbae325 crossref_primary_10_3390_cancers14215273 crossref_primary_10_1007_s11010_022_04425_0 crossref_primary_10_1016_j_clbc_2022_12_013 crossref_primary_10_1016_j_arcmed_2022_12_007 crossref_primary_10_1038_s41598_023_49558_4 crossref_primary_10_1186_s12967_023_04098_3 crossref_primary_10_2147_CMAR_S364346 crossref_primary_10_2217_bmm_2021_0213 crossref_primary_10_1371_journal_pone_0283567 crossref_primary_10_3389_fonc_2021_729230 crossref_primary_10_3390_biom15070971 crossref_primary_10_1002_ange_202217408 crossref_primary_10_1016_j_jobcr_2023_11_003 crossref_primary_10_1111_febs_16331 crossref_primary_10_3389_fonc_2022_777824 crossref_primary_10_1083_jcb_202303102 crossref_primary_10_1186_s40170_022_00280_1 crossref_primary_10_1093_carcin_bgad062 crossref_primary_10_1007_s00432_023_05185_0 crossref_primary_10_1038_s41598_024_68130_2 crossref_primary_10_1007_s10549_021_06463_6 crossref_primary_10_3389_fonc_2023_1013054 crossref_primary_10_1016_j_intimp_2021_107822 crossref_primary_10_3390_ijms24010431 crossref_primary_10_1007_s00784_023_05316_4 crossref_primary_10_1002_advs_202308990 crossref_primary_10_1016_j_bbalip_2025_159609 crossref_primary_10_1016_j_oooo_2023_11_011 crossref_primary_10_1016_j_prp_2025_155938 crossref_primary_10_1177_15330338241245939 crossref_primary_10_3389_fmed_2021_736495 crossref_primary_10_1016_j_heliyon_2024_e36240 crossref_primary_10_3390_cancers13164084 crossref_primary_10_1093_bib_bbae222 crossref_primary_10_1016_j_jormas_2024_101900 crossref_primary_10_1016_j_ijom_2025_01_005 crossref_primary_10_1111_cpr_13402 crossref_primary_10_1007_s00432_024_05853_9 crossref_primary_10_1038_s41417_024_00855_8 crossref_primary_10_1016_j_arabjc_2021_103245 crossref_primary_10_1038_s41418_023_01176_3 crossref_primary_10_1016_j_molcel_2023_10_033 crossref_primary_10_1007_s10528_023_10356_2 crossref_primary_10_1371_journal_pone_0259128 crossref_primary_10_3389_fonc_2022_731528 crossref_primary_10_1038_s41598_022_26000_9 crossref_primary_10_3389_fgene_2023_1028044 crossref_primary_10_1155_2022_8168988 crossref_primary_10_1038_s41419_021_04488_9 crossref_primary_10_1016_j_comtox_2023_100262 crossref_primary_10_1186_s13148_023_01472_2 crossref_primary_10_1016_j_heliyon_2023_e17687 crossref_primary_10_1038_s41419_024_06989_9 crossref_primary_10_1155_2021_5680968 crossref_primary_10_1186_s12935_021_02173_7 crossref_primary_10_1007_s12094_025_03991_1 crossref_primary_10_1016_j_bja_2025_02_042 crossref_primary_10_1016_j_jormas_2023_101734 crossref_primary_10_3389_fphar_2023_1257410 crossref_primary_10_3389_fonc_2021_739182 crossref_primary_10_3389_fmolb_2022_988777 crossref_primary_10_1111_febs_16544 crossref_primary_10_1016_j_bbrc_2024_149965 crossref_primary_10_1007_s13577_021_00575_3 crossref_primary_10_3389_fgene_2022_1008502 crossref_primary_10_1038_s41598_022_14250_6 crossref_primary_10_1038_s42003_021_02225_8 crossref_primary_10_1155_2022_2528164 crossref_primary_10_1007_s00018_022_04277_3 crossref_primary_10_1096_fj_202302386RR crossref_primary_10_1186_s12967_022_03552_y crossref_primary_10_3389_fgene_2021_721021 crossref_primary_10_1016_j_intimp_2022_109169 crossref_primary_10_3390_cells10092246 |
| Cites_doi | 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K 10.1056/NEJMoa052122 10.1517/14728222.2014.906580 10.1016/j.cell.2011.02.013 10.1038/nature16064 10.1046/j.1365-2559.2002.01289.x 10.1093/bioinformatics/18.1.207 10.1186/gb-2010-11-10-r106 10.1007/s13105-016-0524-2 10.1038/sj.onc.1203973 10.1016/j.bbcan.2010.01.005 10.1158/0008-5472.CAN-05-2553 10.1056/NEJMoa052306 10.1182/blood-2005-07-2930 10.1038/ng1861 10.1128/mcb.19.3.2109 10.1002/(sici)1097-0215(19990219)84:1<86::aid-ijc16>3.0.co;2-7 10.1182/blood-2002-06-1743 10.1016/j.bbcan.2016.10.002 10.1007/s10585-008-9207-x 10.1002/path.5028 10.1038/nature10983 10.1016/S0140-6736(05)17947-1 10.1016/S0092-8674(00)81683-9 10.1158/1078-0432.CCR-12-0977 10.1016/j.cell.2018.03.033 10.1200/JCO.2007.15.1068 10.1038/nrc776 10.1002/ijc.24017 10.1073/pnas.0506580102 10.1111/j.1365-2559.2008.03161.x 10.1007/s12032-009-9320-y 10.1016/j.pharmthera.2013.02.003 10.1111/j.1365-2141.2008.07562.x 10.1182/blood.V98.3.787 10.1038/sj.onc.1208555 10.1200/JCO.1983.1.4.227 10.1016/S0140-6736(97)11423-4 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-021-84787-5 |
| DatabaseName | Springer Nature Open Access Journals CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed Publicly Available Content Database CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_4ce5b67313de4acf9c5d1857b1800229 PMC7961001 33723286 10_1038_s41598_021_84787_5 |
| Genre | Journal Article |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFFHD AFPKN CITATION PHGZM PHGZT PJZUB PPXIY PQGLB NPM 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c606t-95507c06dd9e8e7e1c0f6ecb952d389d01829bf2d45ce0bafec6ceb95c596ad33 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 749 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000630516600007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2045-2322 |
| IngestDate | Mon Nov 10 04:35:12 EST 2025 Tue Nov 04 01:53:42 EST 2025 Thu Sep 04 18:02:52 EDT 2025 Tue Oct 07 07:51:00 EDT 2025 Thu Apr 03 06:52:28 EDT 2025 Tue Nov 18 22:12:47 EST 2025 Sat Nov 29 02:21:13 EST 2025 Fri Feb 21 02:38:58 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c606t-95507c06dd9e8e7e1c0f6ecb952d389d01829bf2d45ce0bafec6ceb95c596ad33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2501357528?pq-origsite=%requestingapplication% |
| PMID | 33723286 |
| PQID | 2501357528 |
| PQPubID | 2041939 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_4ce5b67313de4acf9c5d1857b1800229 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7961001 proquest_miscellaneous_2501852487 proquest_journals_2501357528 pubmed_primary_33723286 crossref_citationtrail_10_1038_s41598_021_84787_5 crossref_primary_10_1038_s41598_021_84787_5 springer_journals_10_1038_s41598_021_84787_5 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-03-15 |
| PublicationDateYYYYMMDD | 2021-03-15 |
| PublicationDate_xml | – month: 03 year: 2021 text: 2021-03-15 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2021 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | Espinoza, Miele (CR29) 2013; 139 Furuta, Okuda, Kobayashi, Watabe (CR25) 1805; 141–152 Cooper (CR1) 2018; 244 Bandyopadhyay (CR28) 2005; 24 (CR9) 1998; 351 Jourdan (CR33) 2009; 145 Miller, Thomas, Islam, Muench, Sedoris (CR19) 2012; 18 Anders, Huber (CR36) 2010; 11 Zhao, Song, He, Tang, Zhu (CR17) 2010; 27 Igney, Krammer (CR31) 2002; 2 Weigelt (CR10) 2005; 65 Hofmann (CR34) 2001; 98 Romond (CR7) 2005; 353 Zainuddin, Chua, Tan, Jaafar, Makpol (CR18) 2017; 73 Zheng (CR30) 2015; 527 Curtis (CR13) 2012; 486 Habermann (CR24) 2009; 124 Hanahan, Weinberg (CR3) 2000; 100 Harari, Yarden (CR20) 2000; 19 Sarbia (CR22) 1999; 84 Menyhart (CR5) 1866; 300–319 Wang (CR11) 2005; 365 Stein, Drullinger, Soulard, Dulic (CR16) 1999; 19 Sebio, Kahn, Lenz (CR21) 2014; 18 Holleman (CR32) 2006; 107 Subramanian (CR38) 2005; 102 Vallat (CR35) 2003; 101 Sparano, Paik (CR12) 2008; 26 Hanahan, Weinberg (CR4) 2011; 144 Alo (CR26) 1996; 77 Carter, Eklund, Kohane, Harris, Szallasi (CR23) 2006; 38 Fisher (CR8) 1983; 1 Nosho (CR15) 2008; 53 Ding (CR2) 2018; 173 Kusakabe, Nashimoto, Honma, Suzuki (CR27) 2002; 40 Piccart-Gebhart (CR6) 2005; 353 Fu (CR14) 2008; 25 Sturn, Quackenbush, Trajanoski (CR37) 2002; 18 L Ding (84787_CR2) 2018; 173 I Espinoza (84787_CR29) 2013; 139 A Sebio (84787_CR21) 2014; 18 WK Hofmann (84787_CR34) 2001; 98 D Hanahan (84787_CR3) 2000; 100 MJ Piccart-Gebhart (84787_CR6) 2005; 353 X Zheng (84787_CR30) 2015; 527 L Vallat (84787_CR35) 2003; 101 LA Cooper (84787_CR1) 2018; 244 FH Igney (84787_CR31) 2002; 2 PL Alo (84787_CR26) 1996; 77 B Weigelt (84787_CR10) 2005; 65 T Kusakabe (84787_CR27) 2002; 40 A Sturn (84787_CR37) 2002; 18 C Curtis (84787_CR13) 2012; 486 GH Stein (84787_CR16) 1999; 19 DM Miller (84787_CR19) 2012; 18 ZJ Fu (84787_CR14) 2008; 25 D Harari (84787_CR20) 2000; 19 E Furuta (84787_CR25) 1805; 141–152 M Jourdan (84787_CR33) 2009; 145 EH Romond (84787_CR7) 2005; 353 D Hanahan (84787_CR4) 2011; 144 SL Carter (84787_CR23) 2006; 38 S Bandyopadhyay (84787_CR28) 2005; 24 JK Habermann (84787_CR24) 2009; 124 Y Wang (84787_CR11) 2005; 365 B Fisher (84787_CR8) 1983; 1 M Sarbia (84787_CR22) 1999; 84 JA Sparano (84787_CR12) 2008; 26 A Subramanian (84787_CR38) 2005; 102 K Nosho (84787_CR15) 2008; 53 O Menyhart (84787_CR5) 1866; 300–319 A Holleman (84787_CR32) 2006; 107 S Anders (84787_CR36) 2010; 11 X Zhao (84787_CR17) 2010; 27 A Zainuddin (84787_CR18) 2017; 73 Early Breast Cancer Trialists' Collaborative Group (84787_CR9) 1998; 351 |
| References_xml | – volume: 77 start-page: 474 year: 1996 end-page: 482 ident: CR26 article-title: Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K – volume: 353 start-page: 1673 year: 2005 end-page: 1684 ident: CR7 article-title: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa052122 – volume: 18 start-page: 611 year: 2014 end-page: 615 ident: CR21 article-title: The potential of targeting Wnt/beta-catenin in colon cancer publication-title: Expert Opin. Ther. Targets doi: 10.1517/14728222.2014.906580 – volume: 144 start-page: 646 year: 2011 end-page: 674 ident: CR4 article-title: Hallmarks of cancer: The next generation publication-title: Cell doi: 10.1016/j.cell.2011.02.013 – volume: 527 start-page: 525 year: 2015 end-page: 530 ident: CR30 article-title: Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer publication-title: Nature doi: 10.1038/nature16064 – volume: 40 start-page: 71 year: 2002 end-page: 79 ident: CR27 article-title: Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach publication-title: Histopathology doi: 10.1046/j.1365-2559.2002.01289.x – volume: 18 start-page: 207 year: 2002 end-page: 208 ident: CR37 article-title: Genesis: Cluster analysis of microarray data publication-title: Bioinformatics doi: 10.1093/bioinformatics/18.1.207 – volume: 11 start-page: R106 year: 2010 ident: CR36 article-title: Differential expression analysis for sequence count data publication-title: Genome Biol. doi: 10.1186/gb-2010-11-10-r106 – volume: 73 start-page: 59 year: 2017 end-page: 65 ident: CR18 article-title: gamma-Tocotrienol prevents cell cycle arrest in aged human fibroblast cells through p16(INK4a) pathway publication-title: J. Physiol. Biochem. doi: 10.1007/s13105-016-0524-2 – volume: 19 start-page: 6102 year: 2000 end-page: 6114 ident: CR20 article-title: Molecular mechanisms underlying ErbB2/HER2 action in breast cancer publication-title: Oncogene doi: 10.1038/sj.onc.1203973 – volume: 141–152 start-page: 2010 year: 1805 ident: CR25 article-title: Metabolic genes in cancer: Their roles in tumor progression and clinical implications publication-title: Biochem. Biophys. Acta. doi: 10.1016/j.bbcan.2010.01.005 – volume: 65 start-page: 9155 year: 2005 end-page: 9158 ident: CR10 article-title: Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer publication-title: Can. Res. doi: 10.1158/0008-5472.CAN-05-2553 – volume: 353 start-page: 1659 year: 2005 end-page: 1672 ident: CR6 article-title: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa052306 – volume: 107 start-page: 769 year: 2006 end-page: 776 ident: CR32 article-title: The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia publication-title: Blood doi: 10.1182/blood-2005-07-2930 – volume: 38 start-page: 1043 year: 2006 end-page: 1048 ident: CR23 article-title: A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers publication-title: Nat. Genet. doi: 10.1038/ng1861 – volume: 19 start-page: 2109 year: 1999 end-page: 2117 ident: CR16 article-title: Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts publication-title: Mol. Cell Biol. doi: 10.1128/mcb.19.3.2109 – volume: 84 start-page: 86 year: 1999 end-page: 91 ident: CR22 article-title: Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities publication-title: Int. J. Cancer doi: 10.1002/(sici)1097-0215(19990219)84:1<86::aid-ijc16>3.0.co;2-7 – volume: 101 start-page: 4598 year: 2003 end-page: 4606 ident: CR35 article-title: The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays publication-title: Blood doi: 10.1182/blood-2002-06-1743 – volume: 300–319 start-page: 2016 year: 1866 ident: CR5 article-title: Guidelines for the selection of functional assays to evaluate the hallmarks of cancer publication-title: Biochem. Biophys. Acta. doi: 10.1016/j.bbcan.2016.10.002 – volume: 25 start-page: 887 year: 2008 end-page: 892 ident: CR14 article-title: Overexpression of CyclinD1 and underexpression of p16 correlate with lymph node metastases in laryngeal squamous cell carcinoma in Chinese patients publication-title: Clin. Exp. Metast. doi: 10.1007/s10585-008-9207-x – volume: 244 start-page: 512 year: 2018 end-page: 524 ident: CR1 article-title: PanCancer insights from the cancer genome atlas: The pathologist's perspective publication-title: J. Pathol. doi: 10.1002/path.5028 – volume: 486 start-page: 346 year: 2012 end-page: 352 ident: CR13 article-title: The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups publication-title: Nature doi: 10.1038/nature10983 – volume: 365 start-page: 671 year: 2005 end-page: 679 ident: CR11 article-title: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer publication-title: Lancet doi: 10.1016/S0140-6736(05)17947-1 – volume: 100 start-page: 57 year: 2000 end-page: 70 ident: CR3 article-title: The hallmarks of cancer publication-title: Cell doi: 10.1016/S0092-8674(00)81683-9 – volume: 18 start-page: 5546 year: 2012 end-page: 5553 ident: CR19 article-title: c-Myc and cancer metabolism publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-0977 – volume: 173 start-page: 305 year: 2018 end-page: 320 ident: CR2 article-title: Perspective on oncogenic processes at the end of the beginning of Cancer genomics publication-title: Cell doi: 10.1016/j.cell.2018.03.033 – volume: 26 start-page: 721 year: 2008 end-page: 728 ident: CR12 article-title: Development of the 21-gene assay and its application in clinical practice and clinical trials publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2007.15.1068 – volume: 2 start-page: 277 year: 2002 end-page: 288 ident: CR31 article-title: Death and anti-death: Tumour resistance to apoptosis publication-title: Nat. Rev. Cancer doi: 10.1038/nrc776 – volume: 124 start-page: 1552 year: 2009 end-page: 1564 ident: CR24 article-title: The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome publication-title: Int. J. Cancer doi: 10.1002/ijc.24017 – volume: 102 start-page: 15545 year: 2005 end-page: 15550 ident: CR38 article-title: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.0506580102 – volume: 53 start-page: 588 year: 2008 end-page: 598 ident: CR15 article-title: Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype publication-title: Histopathology doi: 10.1111/j.1365-2559.2008.03161.x – volume: 27 start-page: 985 year: 2010 end-page: 991 ident: CR17 article-title: A novel role of cyclinD1 and p16 in clinical pathology and prognosis of childhood medulloblastoma publication-title: Med. Oncol. doi: 10.1007/s12032-009-9320-y – volume: 139 start-page: 95 year: 2013 end-page: 110 ident: CR29 article-title: Notch inhibitors for cancer treatment publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2013.02.003 – volume: 145 start-page: 45 year: 2009 end-page: 58 ident: CR33 article-title: Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells publication-title: Br. J. Haematol. doi: 10.1111/j.1365-2141.2008.07562.x – volume: 98 start-page: 787 year: 2001 end-page: 794 ident: CR34 article-title: Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray publication-title: Blood doi: 10.1182/blood.V98.3.787 – volume: 24 start-page: 5389 year: 2005 end-page: 5395 ident: CR28 article-title: FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis publication-title: Oncogene doi: 10.1038/sj.onc.1208555 – volume: 1 start-page: 227 year: 1983 end-page: 241 ident: CR8 article-title: Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.1983.1.4.227 – volume: 351 start-page: 1451 year: 1998 end-page: 1467 ident: CR9 article-title: Tamoxifen for early breast cancer: An overview of the randomised trials publication-title: Lancet doi: 10.1016/S0140-6736(97)11423-4 – volume: 65 start-page: 9155 year: 2005 ident: 84787_CR10 publication-title: Can. Res. doi: 10.1158/0008-5472.CAN-05-2553 – volume: 38 start-page: 1043 year: 2006 ident: 84787_CR23 publication-title: Nat. Genet. doi: 10.1038/ng1861 – volume: 102 start-page: 15545 year: 2005 ident: 84787_CR38 publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.0506580102 – volume: 244 start-page: 512 year: 2018 ident: 84787_CR1 publication-title: J. Pathol. doi: 10.1002/path.5028 – volume: 365 start-page: 671 year: 2005 ident: 84787_CR11 publication-title: Lancet doi: 10.1016/S0140-6736(05)17947-1 – volume: 107 start-page: 769 year: 2006 ident: 84787_CR32 publication-title: Blood doi: 10.1182/blood-2005-07-2930 – volume: 98 start-page: 787 year: 2001 ident: 84787_CR34 publication-title: Blood doi: 10.1182/blood.V98.3.787 – volume: 73 start-page: 59 year: 2017 ident: 84787_CR18 publication-title: J. Physiol. Biochem. doi: 10.1007/s13105-016-0524-2 – volume: 53 start-page: 588 year: 2008 ident: 84787_CR15 publication-title: Histopathology doi: 10.1111/j.1365-2559.2008.03161.x – volume: 19 start-page: 6102 year: 2000 ident: 84787_CR20 publication-title: Oncogene doi: 10.1038/sj.onc.1203973 – volume: 40 start-page: 71 year: 2002 ident: 84787_CR27 publication-title: Histopathology doi: 10.1046/j.1365-2559.2002.01289.x – volume: 100 start-page: 57 year: 2000 ident: 84787_CR3 publication-title: Cell doi: 10.1016/S0092-8674(00)81683-9 – volume: 124 start-page: 1552 year: 2009 ident: 84787_CR24 publication-title: Int. J. Cancer doi: 10.1002/ijc.24017 – volume: 24 start-page: 5389 year: 2005 ident: 84787_CR28 publication-title: Oncogene doi: 10.1038/sj.onc.1208555 – volume: 18 start-page: 207 year: 2002 ident: 84787_CR37 publication-title: Bioinformatics doi: 10.1093/bioinformatics/18.1.207 – volume: 527 start-page: 525 year: 2015 ident: 84787_CR30 publication-title: Nature doi: 10.1038/nature16064 – volume: 84 start-page: 86 year: 1999 ident: 84787_CR22 publication-title: Int. J. Cancer doi: 10.1002/(sici)1097-0215(19990219)84:1<86::aid-ijc16>3.0.co;2-7 – volume: 145 start-page: 45 year: 2009 ident: 84787_CR33 publication-title: Br. J. Haematol. doi: 10.1111/j.1365-2141.2008.07562.x – volume: 18 start-page: 5546 year: 2012 ident: 84787_CR19 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-0977 – volume: 101 start-page: 4598 year: 2003 ident: 84787_CR35 publication-title: Blood doi: 10.1182/blood-2002-06-1743 – volume: 27 start-page: 985 year: 2010 ident: 84787_CR17 publication-title: Med. Oncol. doi: 10.1007/s12032-009-9320-y – volume: 19 start-page: 2109 year: 1999 ident: 84787_CR16 publication-title: Mol. Cell Biol. doi: 10.1128/mcb.19.3.2109 – volume: 77 start-page: 474 year: 1996 ident: 84787_CR26 publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K – volume: 11 start-page: R106 year: 2010 ident: 84787_CR36 publication-title: Genome Biol. doi: 10.1186/gb-2010-11-10-r106 – volume: 486 start-page: 346 year: 2012 ident: 84787_CR13 publication-title: Nature doi: 10.1038/nature10983 – volume: 2 start-page: 277 year: 2002 ident: 84787_CR31 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc776 – volume: 353 start-page: 1673 year: 2005 ident: 84787_CR7 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa052122 – volume: 25 start-page: 887 year: 2008 ident: 84787_CR14 publication-title: Clin. Exp. Metast. doi: 10.1007/s10585-008-9207-x – volume: 139 start-page: 95 year: 2013 ident: 84787_CR29 publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2013.02.003 – volume: 141–152 start-page: 2010 year: 1805 ident: 84787_CR25 publication-title: Biochem. Biophys. Acta. doi: 10.1016/j.bbcan.2010.01.005 – volume: 1 start-page: 227 year: 1983 ident: 84787_CR8 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.1983.1.4.227 – volume: 173 start-page: 305 year: 2018 ident: 84787_CR2 publication-title: Cell doi: 10.1016/j.cell.2018.03.033 – volume: 144 start-page: 646 year: 2011 ident: 84787_CR4 publication-title: Cell doi: 10.1016/j.cell.2011.02.013 – volume: 351 start-page: 1451 year: 1998 ident: 84787_CR9 publication-title: Lancet doi: 10.1016/S0140-6736(97)11423-4 – volume: 353 start-page: 1659 year: 2005 ident: 84787_CR6 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa052306 – volume: 300–319 start-page: 2016 year: 1866 ident: 84787_CR5 publication-title: Biochem. Biophys. Acta. doi: 10.1016/j.bbcan.2016.10.002 – volume: 26 start-page: 721 year: 2008 ident: 84787_CR12 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2007.15.1068 – volume: 18 start-page: 611 year: 2014 ident: 84787_CR21 publication-title: Expert Opin. Ther. Targets doi: 10.1517/14728222.2014.906580 |
| SSID | ssj0000529419 |
| Score | 2.7249792 |
| Snippet | Cancer hallmark genes are responsible for the most essential phenotypic characteristics of malignant transformation and progression. In this study, our aim was... Abstract Cancer hallmark genes are responsible for the most essential phenotypic characteristics of malignant transformation and progression. In this study,... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 6047 |
| SubjectTerms | 631/67/1857 631/67/395 631/67/69 Angiogenesis Bladder cancer Brain tumors BRCA1 protein Cancer Cell death Cervical cancer Cervix Deregulation Gene expression Genomes Genomic instability Glioblastoma Glioma Glioma cells Heterogeneity Humanities and Social Sciences Kidneys Metastases multidisciplinary Myc protein Renal cell carcinoma Runx1 protein Science Science (multidisciplinary) Solid tumors Survival Survival analysis Thyroid Thyroid cancer Tumor suppressor genes |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jb9UwEB5VFZW4IKAsgYKCxA2iJt5iHwG14lT1QKXeLMcLVEBe9ZZK_ffM2HmPPpZy4ZqxpdHnsf1NbH8D8Fo51reRy0YYJxqheNdgKHdNEqb33KWkZcjFJvqTE31-bk5vlPqiO2FFHrgAdyh8lIPqecdDFM4n42Ug_aKhI6rD8tM9ZD03kqmi6s2M6Mz0Sqbl-nCBOxW9JmPoDAnSNHJrJ8qC_X9imb9flvzlxDRvRMf34d7EIOt3xfMHsBPHh7BXakpe74M4pb8UOJTzerHCdQAjqXaT8kg9S_Vkoxoq3938a_2ZFrtHcHZ89OnDx2YqjdB4zDiWjSEZMt-qEEzUsY-db5OKfjCSBaQgocW0wQyJBSF9bAeXolc-otlLo1zg_DHsjrMxPoVaC-PFIDkJqQkcT-QnOmCeIgbMxZKQFXRrmKyfdMOpfMU3m8-vubYFWovQ2gytxT5vNn0ui2rGra3fE_qblqR4nT9gHNgpDuy_4qCCg_XY2WkaLizyu44jIWW6glcbM04gOhVxY5ytShstGSZuFTwpQ73xhPMeGadWFfRbQbDl6rZlvPiSRbp7o0jeqoK363D56dbfoXj2P6B4DncZxTndOpQHsLucr-ILuOOvlheL-cs8UX4AnmQTHg priority: 102 providerName: Directory of Open Access Journals |
| Title | Pancancer survival analysis of cancer hallmark genes |
| URI | https://link.springer.com/article/10.1038/s41598-021-84787-5 https://www.ncbi.nlm.nih.gov/pubmed/33723286 https://www.proquest.com/docview/2501357528 https://www.proquest.com/docview/2501852487 https://pubmed.ncbi.nlm.nih.gov/PMC7961001 https://doaj.org/article/4ce5b67313de4acf9c5d1857b1800229 |
| Volume | 11 |
| WOSCitedRecordID | wos000630516600007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M7P dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: 7X7 dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: BENPR dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: PIMPY dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M2P dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RXZC48H4EyipI3CBqEtuxfUIUtYJDVxECaTlFie20FZCUZBeJf89M4k21PHrhMofYlhzPjD0P-xuAF1mZytgxEXFd8ohnLIlQlJOo5loaVta1EnYoNiGXS7Va6dwH3Hp_rXK7Jw4btW0NxcgP8KhOGNoWqXp98T2iqlGUXfUlNPZgTkhlfAbzw6Nl_mGKslAeiyfav5aJmTro8cSiV2UpToqAaSKxcyINwP1_szb_vDT5W-Z0OJCOb__vr9yBW94UDd-MsnMXrrnmHtwYi1P-vA88p3AHykQX9hvcUFAkw9JDmIRtHfo2Ksbyrey-hKe0az6AT8dHH9--i3yNhcig67KONOGZmTizVjvlpEtMXGfOVFqkFm0ZG6P_oas6tVwYF1dl7UxmHDYbobPSMvYQZk3buMcQKq4NrwQjRDaOgoGGjrLo8PAKnbqaiwCS7ToXxgOQUx2Mr8WQCGeqGHlTIG-KgTcFjnk5jbkY4Teu7H1I7Jt6EnT28KHtTguviQU3TlSZZAmzjpem1kZYAsSqErKdUx3A_pZrhdfnvrhkWQDPp2bUREqvlI1rN2MfJVL0AAN4NMrKNBPGJJquKgtA7kjRzlR3W5rzswHtW-qMcLICeLWVt8tp_Xspnlz9F0_hZkoqQBcTxT7M1t3GPYPr5sf6vO8WsCdXcqBq4TVqMQQrkJ6kOVGJdJ6_P8k__wJFOCkh |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9UwEB5VBQQX9kKgQJDgBFETL3F8QIitatXy1EOR3s0ktlMq2qS8vAfqn-I3MpOteiy99cA1tiXH_jyLZ_wNwLM0Zyr2XEZC5yISKU8ihHISlUIry_OyzKRri02oySSbTvXeCvwc3sJQWuUgE1tB7WpLd-QbqKoTjrYFy16ffIuoahRFV4cSGh0sdvzpD3TZmlfb73F_nzO2-WH_3VbUVxWILBrr80gTg5eNU-e0z7zyiY3L1NtCS-ZQe7sYLW5dlMwJaX1c5KW3qfXYbKVOc0cXoCjyL6EcV5RCpqZqvNOhqJlIdP82J-bZRoP6kd6wMVwCosGJ5JL-a8sE_M22_TNF87c4bav-Nm_8bwt3E673hnb4pjsZt2DFV7fhSld68_QOiD26zEHEz8JmgeISD1yY9wQtYV2GfRuVmjnOZ1_DA9IJd-HThUx5DVaruvL3IcyEtqKQnPjmBMIezbjMoTsnCnRZSyEDSIZ9NbanV6cqH0emDfPzzHRYMIgF02LB4JgX45iTjlzk3N5vCS5jTyIGbz_UswPTyxkjrJdFqnjCnRe5LbWVjui-ioQ8A6YDWB9QYnpp1ZgziATwdGxGOUPBo7zy9aLrk0mG_m0A9zpsjjPhXKFhnqUBqCXULk11uaU6_NJymSudEgtYAC8HfJ9N699L8eD8v3gCV7f2P-6a3e3JzkO4xuj4UQqmXIfV-WzhH8Fl-31-2Mwet-c3hM8XjftfIkiBEg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFH6qyiIu7IVAgSDBCaJJvCTxASGgjKgKozmA1JtJvJQKmJRkBtS_xq_jvWzVsPTWA9fYlhz7e5uf_T2AR2nBsthxGQlViEikPIkQyknkhcoML7zPpW2LTWSzWb6_r-Yb8HN4C0PXKged2CpqWxk6I5-gqU44-hYsn_j-WsR8Z_r86FtEFaQo0zqU0-ggsueOf2D41jzb3cG9fszY9PX7V2-ivsJAZNBxX0aK2LxMnFqrXO4yl5jYp86USjKLltzG6H2r0jMrpHFxWXhnUuOw2UiVFpYOQ1H9n8uElCRd79h8PN-hDJpIVP9OJ-b5pEFbSe_ZGC4HUeJEcs0WtiUD_ubn_nld87ecbWsKp1f-50W8Cpd7Bzx80UnMNdhwi-twoSvJeXwDxJwOeVAS6rBZoRpFQQyLnrglrHzYt1EJmq9F_Tk8IFtxEz6cyZS3YHNRLdxtCHOhjCglJx46geKA7l1uMcwTJYayXsgAkmGPtelp16n6xxfdpv95rjtcaMSFbnGhccyTccxRRzpyau-XBJ2xJxGGtx-q-kD3-kcL42SZZjzh1onCeGWkJRqwMqGIgakAtgfE6F6LNfoELgE8HJtR_1BSqVi4atX1ySXDuDeAWx1Ox5lwnqHDnqcBZGsIXpvqesvi8FPLcZ6plNjBAng6YP1kWv9eijun_8UDuIhw1293Z3t34RIjSaSbmXIbNpf1yt2D8-b78rCp77eiHMLHs4b9LwfGid8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pancancer+survival+analysis+of+cancer+hallmark+genes&rft.jtitle=Scientific+reports&rft.au=Nagy%2C+%C3%81d%C3%A1m&rft.au=Munk%C3%A1csy%2C+Gy%C3%B6ngyi&rft.au=Gy%C5%91rffy%2C+Bal%C3%A1zs&rft.date=2021-03-15&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=11&rft.issue=1&rft.spage=6047&rft_id=info:doi/10.1038%2Fs41598-021-84787-5&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |